Sparr H J, Booij L H, Fuchs-Buder T
Abteilung für Anästhesie und Intensivmedizin, Krankenhaus Dornbirn, Lustenaustr. 4, 6850 Dornbirn, Osterreich.
Anaesthesist. 2009 Jan;58(1):66-80. doi: 10.1007/s00101-008-1455-2.
Up to now only acetylcholine esterase inhibitors, such as neostigmine, were available as antagonists of residual neuromuscular blocks. Sugammadex is a modified gamma-cyclodextrin that binds rocuronium and chemically similar aminosteroidal muscle relaxants, such as vecuronium. The underlying mechanism of action is new and differs completely from that of acetylcholine esterase inhibitors. This review summarizes data published so far within the framework of the licensing procedure about the efficacy, safety and side-effects of sugammadex and presents potential new anesthesiological concepts using this compound.
到目前为止,只有乙酰胆碱酯酶抑制剂,如新斯的明,可作为残余神经肌肉阻滞的拮抗剂。舒更葡糖钠是一种修饰的γ-环糊精,它能结合罗库溴铵以及化学结构相似的氨基甾体类肌肉松弛剂,如维库溴铵。其潜在的作用机制是全新的,与乙酰胆碱酯酶抑制剂完全不同。本综述总结了在舒更葡糖钠上市许可程序框架内迄今发表的有关其疗效、安全性和副作用的数据,并提出了使用该化合物的潜在新麻醉学概念。